Tumor-Promoting ATAD2 and Its Preclinical Challenges

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Aug 26

PMID 36008934

Authors

Haicheng Liu

Qianghai Wen

Sheng Yan

Weikun Zeng

Yuhua Zou

Quanliang Liu

Guoxi Zhang

Junrong Zou

Xiaofeng Zou

Affiliations

Soon will be listed here.

Abstract

has received extensive attention in recent years as one prospective oncogene with tumor-promoting features in many malignancies. ATAD2 is a highly conserved bromodomain family protein that exerts its biological functions by mainly AAA ATPase and bromodomain. ATAD2 acts as an epigenetic decoder and transcription factor or co-activator, which is engaged in cellular activities, such as transcriptional regulation, DNA replication, and protein modification. ATAD2 has been reported to be highly expressed in a variety of human malignancies, including gastrointestinal malignancies, reproductive malignancies, urological malignancies, lung cancer, and other types of malignancies. ATAD2 is involved in the activation of multiple oncogenic signaling pathways and is closely associated with tumorigenesis, progression, chemoresistance, and poor prognosis, but the oncogenic mechanisms vary in different cancer types. Moreover, the direct targeting of ATAD2's bromodomain may be a very challenging task. In this review, we summarized the role of ATAD2 in various types of malignancies and pointed out the pharmacological direction.

Citing Articles

Unraveling the potential mechanism and prognostic value of pentose phosphate pathway in hepatocellular carcinoma: a comprehensive analysis integrating bulk transcriptomics and single-cell sequencing data.

Li B, Zeng T, Chen C, Wu Y, Huang S, Deng J Funct Integr Genomics. 2025; 25(1):11.

PMID: 39798003 DOI: 10.1007/s10142-024-01521-w.

FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer.

Rida P, Baker S, Saidykhan A, Bown I, Jinna N Cancers (Basel). 2024; 16(18).

PMID: 39335162 PMC: 11429756. DOI: 10.3390/cancers16183191.

Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population.

An Y, Hung K, Liang C, Tsai C, Tsai C, Chen S J Headache Pain. 2024; 25(1):149.

PMID: 39266962 PMC: 11391721. DOI: 10.1186/s10194-024-01850-y.

Proteomic profiling of urinary extracellular vesicles differentiates breast cancer patients from healthy women.

Jeanmard N, Bissanum R, Sriplung H, Charoenlappanit S, Roytrakul S, Navakanitworakul R PLoS One. 2023; 18(11):e0291574.

PMID: 37922300 PMC: 10624262. DOI: 10.1371/journal.pone.0291574.

Essential role of bromodomain proteins in renal cell carcinoma (Review).

Wen Q, Liu H, Lou K, Zhang X, Chao W, Xin J Mol Med Rep. 2023; 28(1).

PMID: 37293842 PMC: 10280547. DOI: 10.3892/mmr.2023.13026.

References

Groth A, Rocha W, Verreault A, Almouzni G . Chromatin challenges during DNA replication and repair. Cell. 2007; 128(4):721-33. DOI: 10.1016/j.cell.2007.01.030. View

Sun W, Lan X, Zhang H, Wang Z, Dong W, He L . NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis. 2018; 9(3):380. PMC: 5841310. DOI: 10.1038/s41419-018-0418-z. View

Ge T, Liu T, Guo L, Chen Z, Lou G . MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma. Exp Cell Res. 2020; 396(1):112241. DOI: 10.1016/j.yexcr.2020.112241. View

Revenko A, Kalashnikova E, Gemo A, Zou J, Chen H . Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol. 2010; 30(22):5260-72. PMC: 2976367. DOI: 10.1128/MCB.00484-10. View

Zou J, Revenko A, Li L, Gemo A, Chen H . ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A. 2007; 104(46):18067-72. PMC: 2084297. DOI: 10.1073/pnas.0705814104. View

Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y . ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol. 2013; 20 Suppl 3:S577-82. DOI: 10.1245/s10434-013-3027-1. View

Huang J, Yang J, Lei Y, Gao H, Wei T, Luo L . An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development of hepatocellular carcinoma. Oncogenesis. 2016; 5(5):e229. PMC: 4945746. DOI: 10.1038/oncsis.2016.22. View

Glass C, Rosenfeld M . The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000; 14(2):121-41. View

Liu C, Hou J, Shan F, Wang L, Lu H, Ren T . Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis. Onco Targets Ther. 2020; 13:4931-4942. PMC: 7276211. DOI: 10.2147/OTT.S237580. View

10.

Jackson V, Shires A, Tanphaichitr N, Chalkley R . Modifications to histones immediately after synthesis. J Mol Biol. 1976; 104(2):471-83. DOI: 10.1016/0022-2836(76)90282-5. View

11.

Ji S, Su X, Zhang H, Han Z, Zhao Y, Liu Q . MicroRNA-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting in renal cell carcinoma. Oncol Lett. 2019; 17(2):2400-2408. PMC: 6350190. DOI: 10.3892/ol.2018.9871. View

12.

Krakstad C, Tangen I, Hoivik E, Halle M, Berg A, Werner H . ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 2015; 6(29):28440-52. PMC: 4695070. DOI: 10.18632/oncotarget.4955. View

13.

Nayak A, Kumar S, Singh S, Bhattacharyya A, Dixit A, Roychowdhury A . Oncogenic potential of ATAD2 in stomach cancer and insights into the protein-protein interactions at its AAA + ATPase domain and bromodomain. J Biomol Struct Dyn. 2021; 40(12):5606-5622. DOI: 10.1080/07391102.2021.1871959. View

14.

Cao L, Zhang Y, Dong S, Li X, Tong X, Chen D . ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling. J Exp Clin Cancer Res. 2021; 40(1):109. PMC: 7986551. DOI: 10.1186/s13046-021-01905-x. View

15.

Zhang M, Zhang C, Du W, Yang X, Chen Z . ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol. 2015; 18(8):776-81. DOI: 10.1007/s12094-015-1430-8. View

16.

Dewar J, Walter J . Mechanisms of DNA replication termination. Nat Rev Mol Cell Biol. 2017; 18(8):507-516. PMC: 6386472. DOI: 10.1038/nrm.2017.42. View

17.

Zhao Y, Wang Z, Gao M, Wang X, Feng H, Cui Y . lncRNA MALAT1 regulated ATAD2 to facilitate retinoblastoma progression via miR-655-3p. Open Med (Wars). 2021; 16(1):931-943. PMC: 8231467. DOI: 10.1515/med-2021-0290. View

18.

Cattaneo M, Morozumi Y, Perazza D, Boussouar F, Jamshidikia M, Rousseaux S . Lessons from yeast on emerging roles of the ATAD2 protein family in gene regulation and genome organization. Mol Cells. 2014; 37(12):851-6. PMC: 4275701. DOI: 10.14348/molcells.2014.0258. View

19.

Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S . Malignant genome reprogramming by ATAD2. Biochim Biophys Acta. 2013; 1829(10):1010-4. DOI: 10.1016/j.bbagrm.2013.06.003. View

20.

Liu Y, Wang Z, Liu H, Wang X, Zhang Z, Xiao B . Derlin-1 functions as a growth promoter in breast cancer. Biol Chem. 2019; 401(3):377-387. DOI: 10.1515/hsz-2018-0442. View